<DOC>
	<DOCNO>NCT00828997</DOCNO>
	<brief_summary>Previous study analyze serological response follow pneumococcal vaccination use 23-valent vaccination ( Pneumovax ) Rheumatoid Arthritis ( RA ) patient different therapeutic modality include TNF-blockers methotrexate . The result show serological response significantly reduce RA patient receive methotrexate compare receive TNF-blockers . In contrast use polypeptide immunisation ( influenza vaccine ) find anti-TNF significantly impaired serological response compare methotrexate treat RA patient . The aim study analyze serological response Prevenar vaccination patient chronic arthritis study impact different treatment modality serological response . It interest see result different compare one see immunize 23-valent nonconjugated pneumococcal polysaccharide vaccine .</brief_summary>
	<brief_title>Effects Different Anti-rheumatic Treatments Arthritis Antibody Response Following Pneumococcal Vaccination Using PrevenarÂ®</brief_title>
	<detailed_description>Background : Previous study analyze serological response follow pneumococcal vaccination use 23-valent vaccination ( Pneumovax ) Rheumatoid Arthritis ( RA ) patient different therapeutic modality include TNF-blockers methotrexate . The result show serological response significantly reduce RA patient receive methotrexate compare receive TNF-blockers ( Rheumatology ( Oxford ) 2006 Jan ; 45 ( 1 ) :106-11 ) . In contrast use polypeptide immunisation ( influenza vaccine ) find anti-TNF significantly impaired serological response compare methotrexate treat RA patient . The aim study analyze serological response PREVENAR vaccination patient RA spondylarthropathy study impact different treatment modality serological response . It interest see result different compare one see immunize 23-valent nonconjugated pneumococcal polysaccharide vaccine . Study design : Unblinded study RA patient patient spondylarthropathies . All subject vaccinate Prevenar serological response follow blood draw . Patient Population Included : RA patient methotrexate and/or DMARDS RA patient anti-TNF drug monotherapy RA patient anti-TNF +MTX and/or DMARDSs Spondylarthropathy patient anti-TNF drug monotherapy Spondylarthropathy patient anti-TNF drug +MTX Spondylarthropathy patient NSAIDs ( There possibility stratify steroid use ) . Primary Secondary Efficacy Endpoints : Serological response least 2 pneumococcal serotypes include Prevenar vaccine different treatment group . An ethical approval Ethical Review Board Lund University mandatory study well approval Swedish MPA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Age &gt; 18 year Clinical diagnosis RA spondylarthropathy Pregnancy Allergy Has receive pneumococcal vaccination within 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>spondylarthropathy</keyword>
	<keyword>immunological response follow vaccination Prevenar</keyword>
</DOC>